Identifiability analysis of the standard pharmacokinetic models in DCE MR imaging of tumours

Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings

Volumn 26 II, Issue , 2004, Pages 1040-1043

  Lopata, R G P ^a   Van Riel, N A W ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Identifiability; MRI; Pharmacokinetic Model; Tumour

Indexed keywords

COMPUTER SIMULATION; DIFFUSION; INTEGRAL EQUATIONS; MAGNETIC RESONANCE IMAGING; MATHEMATICAL MODELS; MAXIMUM LIKELIHOOD ESTIMATION; MODEL STRUCTURES; PARAMETER ESTIMATION; RELIABILITY; TISSUE; TUMORS; Z TRANSFORMS;

DYNAMIC CONTRAST-ENHANCED MRI (DCE-MRI); IDENTIFIABILITY; PHARMACOKINETIC MODEL; TUMOR TISSUES;

PHARMACOKINETICS;

EID: 11144352759     PISSN: 05891019     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (8)

1. Taylor J.S., Tofts P.S., Port R., Evelhoch J.L., Knopp M., Reddick W.E., Runge V.M., Mayr N., "MR Imaging of Tumor Microcirculation: Promise for the New Millenium." J. Magn Reson Imaging, vol. 10, pp. 903-907, 1999.Tompkins, Ed. Englewood Cliffs, NJ: Prentice-Hall, 1993, ch. 3, pp. 61-74.
2. Rijpkema M., Kaanders J.H.A.M., Joosten F.B.M., Van der Kogel A.J., Heerschap A., Method for Quantitative Mapping of Dynamic MRI Contrast Agent Uptake in Human Tumors. J. Magn Reson Imaging., 2001; 14: 457-463.
3. Jackson A., Quantitative Characterization of Tumor Micro-vasculature using Dynamic Contrast-Enhanced MRI." MedicaMundi, vol. 47, pp. 40-47, 2003.
4. 1-weighted MRI.", Magn. Res. In Med., vol. 45, pp. 601-606, 2001.
5. 1-Weighted MRI of a Diffusable Tracer: Standardized Quantities and Symbols." J. Magn Reson Imaging, vol. 10, pp. 223-232, 1999.
6. Ljung, L., "System Identification: Theory for the user." Prentice Hall Inc, New Jersey, 1999. ISBN: 0-13-656695-2.
7. Pradel C., Siauve N., Bruneteau G., Clement O., Bazelaire C. de, Frouin F., Wedge S.R., Tessier J.L, Robert P.H., Frija G., Cuenod C.A., "Reduced Capillary Perfusion and Permeability in Human Tumour Xenografts treated with the VEGF signalling inhibitor ZD 4190: an in vivo assessment using Dynamic MR imaging and Macromolecular Contrast Media." Magn. Res. Im., vol. 21, pp. 845-851, 2003
8. nd joint EMBS/BMES Conference (IEEE), pp. 1092-1093, 2002.